{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:03:35Z","timestamp":1791083015647,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04733-4","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:40:46Z","timestamp":1761039646000},"page":"4441-4452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world safety profile of opicapone: a comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3247-6904","authenticated-orcid":false,"given":"Li","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-2729","authenticated-orcid":false,"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"2","key":"4733_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1444-0938.2007.00211.x","volume":"91","author":"RA Armstrong","year":"2008","unstructured":"Armstrong RA (2008) Visual signs and symptoms of Parkinson\u2019s disease. Clin Exp Optom 91(2):129\u2013138","journal-title":"Clin Exp Optom"},{"issue":"11","key":"4733_CR2","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord 24(11):1641\u20131649","journal-title":"Mov Disord"},{"key":"4733_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00999","volume":"9","author":"K Barrell","year":"2018","unstructured":"Barrell K, Bureau B, Turcano P, Phillips GD, Anderson JS, Malik A, Shprecher D, Zorn M, Zamrini E, Savica R (2018) High-order visual processing, visual symptoms, and visual hallucinations: a possible symptomatic progression of Parkinson\u2019s disease. Front Neurol 9:999","journal-title":"Front Neurol"},{"issue":"1\u20132","key":"4733_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.01.074","volume":"501","author":"J Bicker","year":"2016","unstructured":"Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falc\u00e3o A (2016) A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. Int J Pharm 501(1\u20132):102\u2013111","journal-title":"Int J Pharm"},{"issue":"6","key":"4733_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535","journal-title":"Lancet Neurol"},{"key":"4733_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132\u2013144","journal-title":"Free Radic Biol Med"},{"key":"4733_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020078","author":"JK Dlay","year":"2020","unstructured":"Dlay JK, Duncan GW, Khoo TK, Williams-Gray CH, Breen DP, Barker RA, Burn DJ, Lawson RA, Yarnall AJ (2020) Progression of neuropsychiatric symptoms over time in an incident Parkinson\u2019s disease cohort (ICICLE-PD). Brain Sci. https:\/\/doi.org\/10.3390\/brainsci10020078","journal-title":"Brain Sci"},{"issue":"3","key":"4733_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40263-021-00888-9","volume":"36","author":"M Fabbri","year":"2022","unstructured":"Fabbri M, Ferreira JJ, Rascol O (2022) COMT inhibitors in the management of Parkinson\u2019s disease. CNS Drugs 36(3):261\u2013282","journal-title":"CNS Drugs"},{"issue":"24","key":"4733_CR9","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351(24):2498\u20132508","journal-title":"N Engl J Med"},{"issue":"5","key":"4733_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/00207454.2021.1929217","volume":"133","author":"M Feldman","year":"2023","unstructured":"Feldman M, Margolesky J (2023) Opicapone for the treatment of Parkinson\u2019s disease: a review. Int J Neurosci 133(5):532\u2013543","journal-title":"Int J Neurosci"},{"issue":"2","key":"4733_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154\u2013165","journal-title":"Lancet Neurol"},{"issue":"8","key":"4733_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/jnnp.2006.103788","volume":"78","author":"CA Haaxma","year":"2007","unstructured":"Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW (2007) Gender differences in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 78(8):819\u2013824","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4733_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00003495-199958010-00017","volume":"58","author":"KJ Holm","year":"1999","unstructured":"Holm KJ, Spencer CM (1999) Entacapone. A review of its use in Parkinson\u2019s disease. Drugs 58(1):159\u2013177","journal-title":"Drugs"},{"issue":"9","key":"4733_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/jcph.514","volume":"55","author":"A Hsu","year":"2015","unstructured":"Hsu A, Yao HM, Gupta S, Modi NB (2015) Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(\u00ae)), sustained-release carbidopa-levodopa (Sinemet(\u00ae) CR), and carbidopa-levodopa-entacapone (Stalevo(\u00ae)). J Clin Pharmacol 55(9):995\u20131003","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"4733_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/14737175.2021.1968298","volume":"21","author":"P Jenner","year":"2021","unstructured":"Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson\u2019s disease: the role of opicapone. Expert Rev Neurother 21(9):1019\u20131033","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"4733_CR16","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/jcpt.13701","volume":"47","author":"JJ Jiang","year":"2022","unstructured":"Jiang JJ, Zhao B, Li J (2022) Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system. J Clin Pharm Ther 47(10):1556\u20131562","journal-title":"J Clin Pharm Ther"},{"issue":"9996","key":"4733_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912","journal-title":"Lancet"},{"issue":"8","key":"4733_CR18","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torr\u00e3o L, Bonif\u00e1cio MJ, Palma PN, Soares-da-Silva P, Learmonth DA (2010) Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 53(8):3396\u20133411","journal-title":"J Med Chem"},{"issue":"2","key":"4733_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197\u2013206","journal-title":"JAMA Neurol"},{"key":"4733_CR20","doi-asserted-by":"crossref","unstructured":"Lin L, Zheng X, Wu M, Chen Y, Nian Q, Lin Y, Chen M (2024) A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for ramucirumab. Expert Opin Drug Saf 1\u201310","DOI":"10.1080\/14740338.2024.2441286"},{"issue":"2","key":"4733_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","volume":"75","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T (2015) Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs 75(2):157\u2013174","journal-title":"Drugs"},{"issue":"2","key":"4733_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.18773\/austprescr.2023.012","volume":"46","author":"Opicapone for Parkinson's disease","year":"2023","unstructured":"Opicapone for Parkinson\u2019s disease (2023) Aust Prescr 46(2):42","journal-title":"Aust Prescr"},{"issue":"2","key":"4733_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"J Parkinson","year":"2002","unstructured":"Parkinson J (2002) An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 14(2):223\u2013236 (discussion 222)","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"20","key":"4733_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O\u2019Brien MD, Silsbee H, Gronseth G, Lang AE (2021) Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee. Neurology 97(20):942\u2013957","journal-title":"Neurology"},{"issue":"5","key":"4733_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000523771","volume":"85","author":"H Reichmann","year":"2022","unstructured":"Reichmann H, Eggert K, Oehlwein C, Warnecke T, Lees AJ, Kemmer M, Soares-da-Silva P (2022) Opicapone use in clinical practice across Germany: a sub-analysis of the OPTIPARK study in Parkinson\u2019s disease patients with motor fluctuations. Eur Neurol 85(5):389\u2013397","journal-title":"Eur Neurol"},{"issue":"8","key":"4733_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.parkreldis.2007.06.015","volume":"13","author":"P Riederer","year":"2007","unstructured":"Riederer P, Gerlach M, M\u00fcller T, Reichmann H (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson\u2019s disease. Parkinsonism Relat Disord 13(8):466\u2013479","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"4733_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","volume":"10","author":"EM Rodriguez","year":"2001","unstructured":"Rodriguez EM, Staffa JA, Graham DJ (2001) The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 10(5):407\u2013410","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"18","key":"4733_CR28","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1080\/14656566.2019.1681971","volume":"20","author":"A Salamon","year":"2019","unstructured":"Salamon A, Z\u00e1dori D, Szpisjak L, Kliv\u00e9nyi P, V\u00e9csei L (2019) Opicapone for the treatment of Parkinson\u2019s disease: an update. Expert Opin Pharmacother 20(18):2201\u20132207","journal-title":"Expert Opin Pharmacother"},{"key":"4733_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789\u2013802","journal-title":"Clin Epidemiol"},{"issue":"7633","key":"4733_CR30","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(69)90837-X","volume":"2","author":"AS Spiers","year":"1969","unstructured":"Spiers AS (1969) Mydriatic responses to sympathomimetic amines in patients treated with L-dopa. Lancet 2(7633):1301","journal-title":"Lancet"},{"issue":"5710","key":"4733_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bmj.2.5710.639","volume":"2","author":"AS Spiers","year":"1970","unstructured":"Spiers AS, Calne DB, Fayers PM (1970) Miosis during L-dopa therapy. Br Med J 2(5710):639\u2013640","journal-title":"Br Med J"},{"issue":"3","key":"4733_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00702-021-02315-1","volume":"128","author":"A Takeda","year":"2021","unstructured":"Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Yoshida K, Hattori N (2021) Long-term safety and efficacy of opicapone in Japanese Parkinson\u2019s patients with motor fluctuations. J Neural Transm 128(3):337\u2013344","journal-title":"J Neural Transm"},{"issue":"8","key":"4733_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm 124(8):901\u2013905","journal-title":"J Neural Transm"},{"issue":"11","key":"4733_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol 157(11):1015\u20131022","journal-title":"Am J Epidemiol"},{"issue":"4","key":"4733_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/8755122520928495","volume":"36","author":"MA Veronin","year":"2020","unstructured":"Veronin MA, Schumaker RP, Dixit R (2020) The irony of MedWatch and the FAERS database: an assessment of data input errors and potential consequences. J Pharm Technol 36(4):164\u2013167","journal-title":"J Pharm Technol"},{"key":"4733_CR36","doi-asserted-by":"publisher","first-page":"1042992","DOI":"10.3389\/fphar.2022.1042992","volume":"13","author":"L Xie","year":"2022","unstructured":"Xie L, Qi X, Wang X, He B, Wang Y, Zhang W, Yu Z, Deng M, Liang S, L\u00fc M (2022) Adverse event profiles of adjuvant treatment with opicapone in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Pharmacol 13:1042992","journal-title":"Front Pharmacol"},{"key":"4733_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103119","volume":"91","author":"Y Yu","year":"2019","unstructured":"Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, Jiang G (2019) Adepedia-on-OHDSI: a next generation pharmacovigilance signal detection platform using the OHDSI common data model. J Biomed Inform 91:103119","journal-title":"J Biomed Inform"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04733-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:58:45Z","timestamp":1772006325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04733-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4733"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04733-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study is a secondary analysis of publicly available summary statistics of cancer incidence and requires no specific ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}